Navigation Links
Treatment of Patients With Malignant Mesothelioma Utilizing Photodynamic Therapy With Pinnacle Biologics' Compound PHOTOFRIN® - Obtains FDA Orphan Drug Designation
Date:12/14/2011

BANNOCKBURN, Ill., Dec. 14, 2011 /PRNewswire/ -- Pinnacle Biologics, Inc., a privately held specialty bio-pharmaceutical company announced today that it has obtained approval for an Orphan Drug Designation (ODD) for their product PHOTOFRIN® (porfimer sodium) as adjuvant therapy to surgery in the treatment of malignant pleural mesothelioma.

Malignant pleural mesothelioma is a form of cancer affecting the lining of the lungs. It is a rare, highly aggressive and devastating cancer with a poor prognosis. The incidence of malignant pleural mesothelioma has been linked to previous asbestos exposure and has grown from almost zero to approximately 3,000 new cases each year in the United States.(1)

"We are pleased to have obtained from the FDA the Orphan Drug Designation for PHOTOFRIN® for treatment in malignant mesothelioma," said Guillermo Herrera, Executive Chairman of Pinnacle Biologics. "Presently, the treatments for mesothelioma are palliative at best, and the outcome in patients with malignant pleural mesothelioma is very poor.  Pinnacle is evaluating current clinical data so as to formulate a plan to bring this important treatment option to patients with malignant pleural mesothelioma in the near future."

According to Patrick Ross, M.D., Ph.D., Professor Clinical Thoracic Surgery, "I am pleased with the FDA decision granting PHOTOFRIN® orphan drug designation for mesothelioma. Photodynamic Therapy (PDT) with PHOTOFRIN® has shown tremendous value as a treatment modality in several forms of cancer providing doctors and health care providers with innovative options to treat unmet medical needs such as mesothelioma and other indications presently under investigation." 

About Photodynamic therapy (PDT) and PHOTOFRIN®

Photodynamic therapy with PHOTOFRIN® is a two-stage process requiring administration of both drug and light. The first stage of PDT is the intravenous injection of PHOTOFRIN®. Illumination with non-burning laser light 40–50 hours following injection with PHOTOFRIN® constitutes the second stage of therapy. When injected, PHOTOFRIN® is attracted to and linger in certain tissues, especially cancer cells, and tumor destruction is by biochemical reactions, not by heat.  Tumor selectivity occurs through a combination of preferential retention of PHOTOFRIN® by the tumor and selective delivery of light to the tumor site.

A novel therapeutic technique, PHOTOFRIN® is FDA approved for the treatment of non-small cell lung cancer (NSCLC) and esophageal cancer. The product is available in the USA, several major European countries, Japan, several Latin American and Southeast Asian markets. Additional approved indications for PHOTOFRIN® include high-grade dysplasia (HGD) in Barrett's esophagus (BE) in North America and papillary bladder cancer in Canada and Argentina.

For additional information about PHOTOFRIN®, please see full prescribing information available at www.photofrin.com.

About Non-Small Cell Lung Cancer(2)

Lung cancer is the leading cause of cancer death in men and women. There are more than 200,000 patients with lung cancer each year. NSCLC is the most common type of lung cancer. It usually grows and spreads more slowly than small cell lung cancer.

There are several types of NSCLC including adenocarcinoma and squamous cell carcinoma. All can be treated with PDT at any stage.

About Esophageal Cancer(3)

Esophageal cancer (EC) forms in tissues lining the esophagus (the muscular tube through which food passes from the mouth to the stomach). There are two types of EC: squamous cell carcinoma and adenocarcinoma. Both types of cancer can be treated with PDT.

It is difficult to determine specific causes of EC. People with certain risk factors, however, are more likely to develop esophageal cancer. These risk factors include male gender, age 65 or older, smoking and heavy alcohol consumption. In 2010, there were approximately 16,600 new cases of EC and 14,500 deaths in the United States.

References:

1.     American Cancer Society - Malignant Mesothelioma – cancer.org
2.     National Center for Biotechnology Information –  PubMed
3.     National Cancer Institute – cancer.gov

About Pinnacle Biologics, Inc.

Pinnacle Biologics specializes in revitalizing healthcare therapies to fulfill their true potential and to maximize favorable patient outcomes. This is accomplished through licensing and acquisition of specialty pharmaceuticals and medical devices. Our innovative approach to opportunity analysis, business development, lifecycle management, regulatory expertise and distribution leverage takes each product to its highest degree of potential and maximum patient benefit.

This press release was funded by Pinnacle Biologics, Inc.  Dr. Patrick Ross has a consultant contract with Pinnacle Biologics as a Scientific Advisor. This press release contains certain "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives and future events. Pinnacle intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21W of the Private Securities Litigation Reform Act of 1995.

CONTACT:
Guillermo Herrera
Executive Chairman
Pinnacle Biologics, Inc.
2801 Lakeside Dr - Suite 209
Bannockburn, IL 60015
P: 1.847.283.7690
F: 1.847.283.7695

www.pinnaclebiologics.com
www.photofrin.com

PHOTOFRIN® is a trademark of Pinnacle Biologics Inc.

 

 


'/>"/>
SOURCE Pinnacle Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Wellington Hospital, New Zealand Becomes First in Southern Hemisphere to Offer Patients Fast and Precise TrueBeam Treatments
2. Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML)
3. S*BIOs Novel JAK2 Inhibitor Pacritinib (SB1518) Effectively Reduces Splenomegaly in Myelofibrosis (MF) Patients With Minimal Impact on Existing Cytopenias Providing Important Therapeutic Niche In Treatment of MF
4. Celladon Corporation Receives FDA Fast Track Designation for Its Investigational Agent MYDICAR® for the Treatment of Heart Failure
5. The European Commission Grants Marketing Authorization for DIFICLIR™ (fidaxomicin) Tablets for Treatment of Clostridium difficile Infections
6. Weight Loss and Effects on Diabetes with Qnexa Treatment Results Presented at the World Diabetes Congress
7. First Patient Enrolled in Therakos Phase Two Study for Treatment of Graft-versus-Host Disease
8. Ceregene Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinsons Disease
9. Mylan Committed to Expanding Access in Developing Countries to High Quality, Affordable HIV/AIDS Treatment
10. Philips Answers the Call for Worldwide Access to Advanced Imaging Systems for Diagnosis and Treatment
11. SRI Researchers Validate Preclinical Effectiveness of Tuberculosis Drug Target that Could Shorten Treatment Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Fla. , Feb. 11, 2016 ... ) company providing high-quality specialty pharmacy care for ... announced today it has achieved full Specialty Pharmacy ... accrediting organization dedicated to promoting health care quality ... --> --> The URAC accreditation ...
(Date:2/11/2016)... , Feb. 11, 2016  M3 Biotechnology Inc., spurred by a major "team investment" by ... brother, Michael, has completed an oversubscribed Series A-Round, according to CEO Leen Kawas , PhD. ... ... ... ...
(Date:2/11/2016)... 11, 2016 SI-BONE, Inc., a medical ... iFuse Implant System, a minimally invasive surgical (MIS) ... the sacroiliac (SI) joint, announced the publication of ... MIS SI joint fusion for patients suffering from ... or SI joint disruption.  In the first article, ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 12, 2016 , ... The Journal of ... from 0.416 in 2013. The SJR uses data taken from the Scopus database (Elsevier ... the number of citations received by the journal over a three year period and ...
(Date:2/11/2016)... ... 2016 , ... The president released a FY 2017 budget request on Tuesday ... of the cost burden to military beneficiaries. , MOAA’s president, retired Air Force ... as including limited quantifiable benefit fixes mixed with numerous beneficiary fee hikes. , “We ...
(Date:2/11/2016)... ... 11, 2016 , ... Hall Integrative Health and Chiropractic, PC ... simultaneous grand openings in March. All seven practices are set to start accepting ... reversing diabetes possible? According to this 2011 CNN article it is possible: ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... women’s health, is pleased to announce the promotions of Allison Kelly to executive ... Steve Catone to executive vice president of North American capital sales, and Wendy ...
(Date:2/11/2016)... ... 2016 , ... Atlantic Information Services, Inc. (AIS) is pleased ... Study for Plans and Purchasers.” Executives from Intel Corp. and Providence Health & ... health benefits program Connected Care, will discuss the challenges they faced (and how ...
Breaking Medicine News(10 mins):